Liraglutide, a glucagon-like peptide 1 receptor (GLP-1R) agonist, is a novel hypoglycemic agent recommended by the latest guidelines for treating type 2 diabetes and comorbid ASCVD due to its proven cardiovascular benefits [6–8]. This evidence concerns the gene GLP1R and atherosclerosis.